Company Overview and News

 
ATL1103 Phase II Trial Results Published in the European Journal of Endocrinology

2018-05-23 accesswire
MELBOURNE, AUSTRALIA / ACCESSWIRE / May 23, 2018 / Antisense Therapeutics (the "Company" or "ANP") (ASX: ANP; OTC PINK: ATHJF) is pleased to announce the acceptance for publication of previously reported positive Phase II clinical trial data on ATL1103 (atesidorsen) in the leading peer-reviewed medical journal, the European Journal of Endocrinology.

 
Antisense Therapeutics raising $5+ million for muscle-wasting disease trials

2018-04-06 proactiveinvestors.com.au
Antisense Therapeutics Limited (ASX:ANP) has successfully completed a share placement to Australian Ethical Investment to raise $581,614 at 2.4 cents each.

 
Approval Received for Phase II Trial of ATL1102 in Duchenne Muscular Dystrophy

2018-02-28 accesswire
MELBOURNE, AUSTRALIA / ACCESSWIRE / February 28, 2018 / Antisense Therapeutics ("ANP" or the "Company") (ASX: ANP; OTC PINK: ATHJF) is pleased to advise that the Company has received approval from the Royal Children's Hospital (RCH), Melbourne Human Research Ethics Committee, to undertake a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD), an incurable muscle-wasting disease of children.

2
Prostate Cancer Pipeline H1 2017 Therapeutic Key Players 3-V Biosciences Inc, 4SC AG, Actinium Pharmaceuticals Inc and Advaxis Inc, Says a New Research Report at RnRMarketResearch.com

2017-07-11 prnewswire
Prostate Cancer Pipeline Review, H1 2017 is new research report highlights details analysis includes 1845 pages with latest updates, Drug Profiles, Key players, Table of Contents, List of Tables, List of Figures.

 
Antisense Therapeutics to commence muscular dystrophy trials

2017-06-26 proactiveinvestors.com.au
Antisense Therapeutics (ASX:ANP) is planning to undertake a clinical trial of its immunomodulatory therapy ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).

 
Pipeline of Asthma Market Covering 129 Companies Reviewed for H1 2016 in New Research Report

2016-05-31 prnewswire
RnRMarketResearch.com adds "Asthma - Pipeline Review, H1 2016" market research report with comparative analysis of Asthma therapy at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects.

 
 
Appendix 4C - quarterly

2016-04-22 asx.com.au

 
Antisense Therapeutics Limited in ASX trading halt

2016-03-09 proactiveinvestors.com.au
Antisense Therapeutics Limited is preparing to outline details in relation to the ATL1103 program for multiple sclerosis

 
COR-004/ATL1103 Project Update

2016-03-09 asx.com.au

 
Trading Halt

2016-03-07 asx.com.au

 
Trading Halt Request

2016-03-07 asx.com.au

 
Half Yearly Report and Accounts

2016-02-23 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...